Lacticaseibacillus Rhamnosus Drug Interactions, Uses, Effectiveness, Safety & More
What is this page for?
First and foremost: how Lacticaseibacillus Rhamnosus interacts with medications. The heart of this page is the interaction list — every drug Lacticaseibacillus Rhamnosus is known to interact with, and how serious each one is.
But these pages have grown well beyond that into a full monograph — what Lacticaseibacillus Rhamnosus is, what people use it for and how strong the evidence is, its safety and side effects, and answers to the questions we’re asked most — written and reviewed by the clinical staff at HelloPharmacist. It’s educational information from our licensed clinical databases, not medical advice, and we don’t sell or endorse products. Our editorial policy
Check Lacticaseibacillus Rhamnosus against your medication
Add one medicationDrugs that interact with Lacticaseibacillus Rhamnosus
182 medications have a known interaction with Lacticaseibacillus Rhamnosus, graded by severity. Select any drug for the full evidence-based detail.
Don’t want to scroll the list? Just ask.
Tell us the medications you take and we’ll check each one against Lacticaseibacillus Rhamnosus using our pharmacist-reviewed interaction data.
AI summaries are generated from our Lacticaseibacillus Rhamnosus interaction data for education only — always confirm with your pharmacist. How we use AI
No drugs match “”.
What Severity, Likelihood & Evidence Mean
Severity — How Serious It Can Be
- Major. Clinically significant; generally best avoided, or used only under direct professional supervision.
- Moderate. May need monitoring, a dose adjustment, or separating the times you take each one.
- Minor. Generally not clinically significant, but still worth noting and mentioning to your pharmacist.
- No known interaction. Checked against our sources with nothing documented — not the same as proven safety.
Likelihood — How Well It’s Documented
- Likely. Well-controlled human studies have demonstrated the likely existence of this interaction
- Probable. Interaction has not been documented in well-controlled studies, however, the interaction has been demonstrated in some small human studies or in controlled animal studies in conjunction with multiple case reports.
- Possible. Interaction has been documented in animal or in lab research, or the interaction has been documented in humans but is limited to case reports or conflicting clinical research exists
- Unlikely. Interaction has been demonstrated in animal or in lab research but has been shown not to occur in humans.
Where This Data Comes From
- Interaction records are evidence-graded and sourced from the Natural Medicines database (TRC Healthcare), the same reference used by pharmacists and hospitals.
- Each drug listed above links to the full report for that exact Lacticaseibacillus Rhamnosus combination — clinical detail, likelihood, evidence level, and citations.
- Content is reviewed by licensed HelloPharmacist pharmacists — see our data sources and editorial standards.
The kinds of drugs Lacticaseibacillus Rhamnosus affects
Every type of medication (drug category) Lacticaseibacillus Rhamnosus is known to interact with. Open any category for the detail — or search your exact drug in the checker above.
Antibiotic Drugs
Theoretically, taking Lacticaseibacillus rhamnosus with antibiotic drugs might decrease the effectiveness of L. rhamnosus.
L. rhamnosus preparations usually contain live and active organisms. Therefore, simultaneously taking antibiotics might kill a significant number of the organisms. Tell patients to separate administration of antibiotics and L. rhamnosus preparations by at least two hours.
Lacticaseibacillus Rhamnosus: Uses, Safety & Side Effects
Lacticaseibacillus rhamnosus (often labeled L. rhamnosus GG) is a well-studied probiotic bacterium used mainly for diarrhea and general gut health. It is considered safe for most healthy people, with the best evidence for preventing certain types of diarrhea, but benefits for many other uses are uncertain. People who are seriously ill or have weakened immune systems should check with a doctor first.
- Scientific name
- Lacticaseibacillus rhamnosus
- Family
- Lactobacillaceae
- Part used
- Whole live bacteria (probiotic strain)
- Common forms
- Capsules, tablets, powders, sachets, drops, fermented dairy products (yogurt, kefir)
- Diarrhea (including antibiotic-related)
- Digestive health
- Vaginal and urinary health
- Eczema and allergy prevention in children
- Immune support
Popular and traditional uses — not proof it works. See “Uses & effectiveness” below for the evidence.
Generally well tolerated in healthy people, though serious infections have rarely occurred in very ill or immunocompromised individuals.
When used orally and appropriately. Lacticaseibacillus rhamnosus GG has been used with apparent safety starting 2-4 weeks before delivery. L. rhamnosu...
Read the full pregnancy detailWhen used orally and appropriately. Lacticaseibacillus rhamnosus GG has been used with apparent safety when breastfeeding for up to six months and L....
Read the full breastfeeding detailPregnancy & breastfeeding ratings are from Natural Medicines (Therapeutic Research Center). Safety guidance is general; always confirm with your pharmacist or doctor for your situation.
Overview
Lacticaseibacillus rhamnosus is a type of friendly bacteria (a probiotic) that naturally lives in the human gut. It was once classified under the name Lactobacillus rhamnosus, and many products still use that older name. One of the most famous versions is the strain called L. rhamnosus GG (LGG).
This bacterium is a lactic acid producer, meaning it helps ferment sugars into lactic acid. It is found in some fermented foods and dairy products and is also added to many supplements. People take it to support digestion, immune health, and the balance of bacteria in the gut.
Probiotics like this one are sold as capsules, powders, drops, and in fortified foods such as certain yogurts and kefir.
How it works
Probiotics like L. rhamnosus are thought to work in several ways. They may help crowd out harmful bacteria by competing for space and nutrients in the gut. They also produce lactic acid and other substances that can make the environment less friendly to some germs.
This bacterium may also support the lining of the intestines and interact with the immune system in ways that could affect inflammation. Much of this understanding comes from laboratory and animal research, and how strongly these effects apply in everyday human use is still being studied.
Does Lacticaseibacillus Rhamnosus work?
How to read these evidence grades
Natural Medicines’ 7-point scale. We show each rating’s label word-for-word.
Possibly Effective Antibiotic-associated diarrhea
Oral Lacticaseibacillus rhamnosus GG seems to reduce the risk of antibiotic-associated diarrhea (AAD) in adults and children.
Possibly Effective Atopic dermatitis (eczema)
Oral live Lacticaseibacillus rhamnosus, alone or in combination with other probiotics, seems to be beneficial for the treatment of atopic dermatitis in infants and children. It also seems to be beneficial for preventing atopic dermatitis when taken by the infant after exposure during pregnancy, but it is unclear if taking L. rhamnosus only during pregnancy or lactation is beneficial for preventing atopic dermatitis.
Possibly Effective Atopic disease
Taking oral Lacticaseibacillus rhamnosus GG during pregnancy and when breastfeeding, or giving it to the infant, seems to prevent atopic disease in infants and children.
Possibly Ineffective Critical illness (trauma)
Enteral Lacticaseibacillus rhamnosus does not seem to be beneficial for patients with critical illness.
Possibly Ineffective Peanut allergy
Oral Lacticaseibacillus rhamnosus does not seem to be beneficial for increasing the efficacy of peanut oral immunotherapy in children.
Possibly Ineffective Ventilator-associated pneumonia (VAP)
Most research shows that enteral Lacticaseibacillus rhamnosus does not prevent VAP and might increase the risk of L. rhamnosus infection.
Also studied for 57 conditions — evidence insufficient to rate
Insufficient Reliable Evidence To Rate Abdominal pain
It is unclear if oral Lacticaseibacillus rhamnosus is beneficial for abdominal pain.
Insufficient Reliable Evidence To Rate Age-related cognitive decline
It is unclear if oral Lacticaseibacillus rhamnosus is beneficial for age-related cognitive decline.
Insufficient Reliable Evidence To Rate Allergic rhinitis (hay fever)
Oral Lacticaseibacillus rhamnosus has only been evaluated in combination with other ingredients; its effect when used alone is unclear.
Insufficient Reliable Evidence To Rate Attention deficit-hyperactivity disorder (ADHD)
Although there has been interest in using oral Lacticaseibacillus rhamnosus for ADHD prevention or treatment, there is insufficient reliable information about the clinical effects of L. rhamnosus for this purpose.
Insufficient Reliable Evidence To Rate Bacterial vaginosis
Oral and vaginal Lacticaseibacillus rhamnosus have only been evaluated in combination with other ingredients; their effect when used alone is unclear.
Insufficient Reliable Evidence To Rate Bipolar disorder
Oral Lacticaseibacillus rhamnosus has only been evaluated in combination with other ingredients; its effect when used alone is unclear.
Insufficient Reliable Evidence To Rate Cancer
Although there has been interest in using oral Lacticaseibacillus rhamnosus for cancer prevention or treatment, there is insufficient reliable information about the clinical effects of L. rhamnosus for this condition.
Insufficient Reliable Evidence To Rate Canker sores
It is unclear if oral Lacticaseibacillus rhamnosus is beneficial for canker sore prevention or treatment.
Insufficient Reliable Evidence To Rate Chemotherapy-induced diarrhea
It is unclear if oral Lacticaseibacillus rhamnosus is beneficial for preventing chemotherapy-induced diarrhea.
Insufficient Reliable Evidence To Rate Child development
Oral Lacticaseibacillus rhamnosus has only been evaluated in combination with other ingredients; its effect when used alone is unclear.
Insufficient Reliable Evidence To Rate Clostridioides difficile infection
It is unclear if oral Lacticaseibacillus rhamnosus is beneficial for the prevention of C. difficile infection.
Insufficient Reliable Evidence To Rate Cognitive function
It is unclear if oral Lacticaseibacillus rhamnosus improves cognitive function in young adults.
Insufficient Reliable Evidence To Rate Cognitive impairment
It is unclear if oral Lacticaseibacillus rhamnosus is beneficial for cognitive impairment.
Insufficient Reliable Evidence To Rate Colic
It is unclear if oral Lacticaseibacillus rhamnosus is beneficial for colic.
Insufficient Reliable Evidence To Rate Common cold
Although there has been interest in using oral Lacticaseibacillus rhamnosus for preventing the common cold, there is insufficient reliable information about the clinical effects of L. rhamnosus for this condition.
Insufficient Reliable Evidence To Rate Constipation
It is unclear if oral Lacticaseibacillus rhamnosus is beneficial for constipation.
Insufficient Reliable Evidence To Rate Coronavirus disease 2019 (COVID-19)
Although there has been interest in using oral Lacticaseibacillus rhamnosus for reducing symptoms of COVID-19, there is insufficient reliable information about the clinical effects of L. rhamnosus for this condition.
Insufficient Reliable Evidence To Rate Crohn disease
It is unclear if oral Lacticaseibacillus rhamnosus is beneficial for preventing Crohn disease recurrence.
Insufficient Reliable Evidence To Rate Cystic fibrosis
It is unclear if oral Lacticaseibacillus rhamnosus is beneficial for cystic fibrosis.
Insufficient Reliable Evidence To Rate Dental caries
It is unclear if oral Lacticaseibacillus rhamnosus is beneficial for dental caries prevention.
Insufficient Reliable Evidence To Rate Dental plaque
Oral Lacticaseibacillus rhamnosus has only been evaluated in combination with other ingredients; its effect when used alone is unclear.
Insufficient Reliable Evidence To Rate Denture stomatitis
Although there has been interest in using oral Lacticaseibacillus rhamnosus for denture stomatitis, there is insufficient reliable information about the clinical effects of L. rhamnosus for this condition.
Insufficient Reliable Evidence To Rate Diabetes
It is unclear if oral Lacticaseibacillus rhamnosus is beneficial for treatment of type 1 or type 2 diabetes. Oral L. rhamnosus is unlikely to be beneficial for the prevention of gestational diabetes and may actually increase the risk for other complications.
Insufficient Reliable Evidence To Rate Diarrhea
It is unclear if oral Lacticaseibacillus rhamnosus is beneficial for the prevention or treatment of acute diarrhea.
Insufficient Reliable Evidence To Rate Gingivitis
Oral Lacticaseibacillus rhamnosus has only been evaluated in combination with other ingredients; its effect when used alone is unclear.
Insufficient Reliable Evidence To Rate Group B streptococcal colonization
Oral Lacticaseibacillus rhamnosus has only been evaluated in combination with other ingredients; its effect when used alone is unclear.
Insufficient Reliable Evidence To Rate Helicobacter pylori
It is unclear if oral Lacticaseibacillus rhamnosus in combination with standard therapies for H. pylori can improve eradication rates or reduce the risk of adverse effects; the available research is conflicting.
Insufficient Reliable Evidence To Rate HIV/AIDS
Although there has been interest in using oral Lacticaseibacillus rhamnosus for HIV/AIDS, there is insufficient reliable information about the clinical effects of L. rhamnosus for this condition.
Insufficient Reliable Evidence To Rate Hypercholesterolemia
Although there has been interest in using oral Lacticaseibacillus rhamnosus for hypercholesterolemia, there is insufficient reliable information about the clinical effects of L. rhamnosus for this condition.
Insufficient Reliable Evidence To Rate Hypertension
Although there has been interest in using oral Lacticaseibacillus rhamnosus for hypertension, there is insufficient reliable information about the clinical effects of L. rhamnosus for this condition.
Insufficient Reliable Evidence To Rate Irritable bowel syndrome (IBS)
It is unclear if oral Lacticaseibacillus rhamnosus is beneficial for IBS; the available research is conflicting.
Insufficient Reliable Evidence To Rate Lactose intolerance
It is unclear if oral Lacticaseibacillus rhamnosus is beneficial for lactose intolerance.
Insufficient Reliable Evidence To Rate Malnutrition
Oral Lacticaseibacillus rhamnosus has only been evaluated in combination with other ingredients; its effect when used alone is unclear.
Insufficient Reliable Evidence To Rate Metabolic syndrome
Although there has been interest in using oral Lacticaseibacillus rhamnosus for metabolic syndrome, there is insufficient reliable information about the clinical effects of L. rhamnosus for this condition.
Insufficient Reliable Evidence To Rate Necrotizing enterocolitis (NEC)
It is unclear if oral Lacticaseibacillus rhamnosus is beneficial or safe for NEC prevention.
Insufficient Reliable Evidence To Rate Neurogenic bladder
Although there has been interest in using intravesical Lacticaseibacillus rhamnosus for reducing urinary symptoms associated with neurogenic bladder, there is insufficient reliable information about the clinical effects of L. rhamnosus for this purpose.
Insufficient Reliable Evidence To Rate Nonalcoholic fatty liver disease (NAFLD)
Oral Lacticaseibacillus rhamnosus has only been evaluated in combination with other ingredients; its effect when used alone is unclear.
Insufficient Reliable Evidence To Rate Obesity
It is unclear if oral Lacticaseibacillus rhamnosus is beneficial for weight loss.
Insufficient Reliable Evidence To Rate Oropharyngeal candidiasis
Although there has been interest in using oral Lacticaseibacillus rhamnosus for oropharyngeal candidiasis, there is insufficient reliable information about the clinical effects of L. rhamnosus for this condition.
Insufficient Reliable Evidence To Rate Osteoarthritis
Although there has been interest in using oral Lacticaseibacillus rhamnosus for osteoarthritis, there is insufficient reliable information about the clinical effects of L. rhamnosus for this condition.
Insufficient Reliable Evidence To Rate Otitis media
It is unclear if oral Lacticaseibacillus rhamnosus is beneficial for preventing otitis media in children.
Insufficient Reliable Evidence To Rate Periodontitis
It is unclear if oral Lacticaseibacillus rhamnosus is beneficial for periodontitis.
Insufficient Reliable Evidence To Rate Polycystic ovary syndrome (PCOS)
It is unclear if oral Lacticaseibacillus rhamnosus is beneficial for PCOS.
Insufficient Reliable Evidence To Rate Postoperative infection
It is unclear if oral Lacticaseibacillus rhamnosus is beneficial for preventing postoperative infections.
Insufficient Reliable Evidence To Rate Postoperative recovery
It is unclear if oral Lacticaseibacillus rhamnosus is beneficial for improving postoperative recovery.
Insufficient Reliable Evidence To Rate Postpartum depression
It is unclear if oral Lacticaseibacillus rhamnosus is beneficial for postpartum depression.
Insufficient Reliable Evidence To Rate Pouchitis
Although there has been interest in using oral Lacticaseibacillus rhamnosus for pouchitis, there is insufficient reliable information about the clinical effects of L. rhamnosus for this condition.
Insufficient Reliable Evidence To Rate Respiratory tract infections
It is unclear if oral Lacticaseibacillus rhamnosus is beneficial for respiratory tract infections; the available research is conflicting.
Insufficient Reliable Evidence To Rate Rheumatoid arthritis (RA)
It is unclear if oral Lacticaseibacillus rhamnosus is beneficial for RA.
Insufficient Reliable Evidence To Rate Rotaviral diarrhea
It is unclear if oral Lacticaseibacillus rhamnosus is beneficial for rotaviral diarrhea.
Insufficient Reliable Evidence To Rate Short bowel syndrome
Although there has been interest in using oral Lacticaseibacillus rhamnosus for short bowel syndrome, there is insufficient reliable information about the clinical effects of L. rhamnosus for this condition.
Insufficient Reliable Evidence To Rate Small intestinal bacterial overgrowth (SIBO)
Although there has been interest in using oral Lacticaseibacillus rhamnosus for SIBO, there is insufficient reliable information about the clinical effects of L. rhamnosus for this condition.
Insufficient Reliable Evidence To Rate Stress
It is unclear if oral Lacticaseibacillus rhamnosus GG is beneficial for stress.
Insufficient Reliable Evidence To Rate Travelers' diarrhea
It is unclear if oral Lacticaseibacillus rhamnosus GG is beneficial for the prevention of travelers' diarrhea; the available research is conflicting.
Insufficient Reliable Evidence To Rate Ulcerative colitis
Although there has been interest in using oral Lacticaseibacillus rhamnosus for ulcerative colitis, there is insufficient reliable information about the clinical effects of L. rhamnosus for this condition.
Insufficient Reliable Evidence To Rate Urinary tract infections (UTIs)
It is unclear if oral or intravaginal Lacticaseibacillus rhamnosus is beneficial for the prevention or treatment of UTIs.
Insufficient Reliable Evidence To Rate Vaginal candidiasis
It is unclear if oral or intravaginal Lacticaseibacillus rhamnosus is beneficial for the prevention or treatment of vaginal candidiasis.
Source & disclaimer. Effectiveness ratings and evidence summaries are provided by Natural Medicines (Therapeutic Research Center) and shown as licensed. Where Natural Medicines hasn’t rated a use, HelloPharmacist’s pharmacists may add their own reviewed rating and evidence (each such entry is labeled). This is educational information, not medical advice — talk with your pharmacist or doctor before starting, stopping, or changing a supplement.
Safety & precautions
For most healthy people, L. rhamnosus is considered safe and is widely used. However, in rare cases probiotics have been linked to serious infections (such as bloodstream infections) in people who are very ill, hospitalized, have weakened immune systems, or have central venous catheters. These individuals should not take probiotics without medical supervision.
People with serious underlying conditions, premature infants, and those recovering from major surgery should talk to a doctor before using probiotics.
Pregnancy and breastfeeding: Probiotics are often considered low risk, but solid safety data are limited. To be cautious, pregnant and breastfeeding people should use it only after checking with their doctor or pharmacist.
Side effects
Side effects are usually mild. The most common ones include gas, bloating, and mild stomach discomfort, which often improve as your body adjusts.
Serious side effects are rare in healthy people. In rare cases, especially among severely ill or immunocompromised individuals, probiotic bacteria have caused infections. Stop use and seek medical care if you develop fever, severe abdominal pain, or signs of infection.
Lacticaseibacillus Rhamnosus: Reported Adverse Effects
Documented safety reports on Lacticaseibacillus Rhamnosus from the evidence-graded Natural Medicines (TRC Healthcare) database, shown word-for-word from the licensed record.
Reports by conditionAllergic rhinitis (hay fever) Gastrointestinal
Orally, taking Lacticaseibacillus rhamnosus alone or in combination with other probiotics may cause gastrointestinal side effects including diarrhea; however, these events are uncommon. In one small clinical study in infants with suspected cow's milk allergy who were receiving extensively hydrolyzed whey formula, diarrhea occurred in 5 of 13 infants receiving non-viable, heat-killed L. rhamnosus, compared with 0 of 14 infants receiving live L. rhamnosus and 0 of 8 infants receiving placebo.
A 31-year-old male developed severe L. rhamnosus GG stomatitis and oral ulcers while undergoing induction chemotherapy for acute myeloid leukemia. The strain in the ulcers was determined to be the same strain that had been consumed in dairy products.
- Beerepoot MA, ter Riet G, Nys S, van der Wal WM, de Borgie CA, de Reijke TM,Prins JM, Koeijers J, Verbon A, Stobberingh E, Geerlings SE. Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in p
- Kirjavainen PV, Salminen SJ, Isolauri E. Probiotic bacteria in the management of atopic disease: underscoring the importance of viability. J Pediatr Gastroenterol Nutr. 2003;36(2):223-7.
- Ishihara Y, Kanda J, Tanaka K, et al. Severe oral infection due to Lactobacillus rhamnosus during induction chemotherapy for acute myeloid leukemia. Int J Hematol 2014;100(6):607-10.
Antibiotic-associated diarrhea Immunologic
Since Lacticaseibacillus rhamnosus preparations contain live and active microorganisms, there is some concern that they might cause pathological infection in some patients. Some lactobacilli species have been isolated in some cases of bacteremia, sepsis, splenic abscess, endocarditis, necrotizing fasciitis, pancreatic necrosis, and meningoencephalitis. Most of these cases are thought to be due to the translocation of bacteria from other locations in the body in which they occur naturally, such as the oral cavity and gastrointestinal system, in ill and/or immunocompromised patients, or in patients otherwise at risk of infection. However, there are also rare case reports of pathological infections possibly to intake of L. rhamnosus products in these populations.
Case reports exist of bacteremia or sepsis associated with L. rhamnosus use in infants and children. In infants, some cases have occurred following the use of L. rhamnosus for the treatment or prevention of diarrhea. These cases include a severely ill 6-week-old infant given L. rhamnosus GG (Culturelle) for antibiotic-associated diarrhea, a 6-day old with intrauterine growth restriction given L. rhamnosus GG to prevent antibiotic-associated diarrhea, a 3-month-old infant given L. rhamnosus GG for the prevention of antibiotic-associated diarrhea, and a 18-day-old preterm, very-low-birthweight infant given L. rhamnosus GG for the prevention of necrotizing enterocolitis. In other cases, infants with short bowel syndrome have developed bacteremia. One case report involved an 11-month-old infant receiving L. rhamnosus for 5 weeks through a gastrostomy tube for rotaviral diarrhea. Lactobacillus sepsis has also occurred in a 6-year-old child with cerebral palsy following use of L. rhamnosus GG (Culturelle) for intermittent diarrhea. A 17-year-old male with ulcerative colitis developed bacteremia following once daily use of L. rhamnosus GG 1 billion colony-forming units (CFUs) (Culturelle, ConAgra Foods).
There are also cases of L. rhamnosus bacteremia or sepsis in adults. Fatal L. rhamnosus septicemia has been reported in an immunocompromised patient consuming yogurt and taking prolonged courses of multiple broad spectrum antibiotics. A 50-year-old male developed L. rhamnosus endocarditis following daily use of a probiotic product providing at least 5 billion CFUs of L. rhamnosus. Although the patient was considered healthy, the role of a previous diagnosis of an unspecified heart murmur or an untreated deep gingival cut 3 months prior to endocarditis diagnosis may have increased the risk of infection. A 56-year-old immunocompetent female developed L. rhamnosus GG bacteremia. She was hospitalized with an indwelling catheter following a motor vehicle accident and had been given this strain following the onset of diarrhea via a nasogastric tube as per hospital protocol. There is also a case of L. rhamnosus sepsis in a male in his late 60s with a bioprosthetic aortic valve. He was taking L. rhamnosus for ulcerative colitis and developed sepsis along with aortic valve endocarditis and septic emboli to the brain.
A specific probiotic preparation (NBL probiotic ATP, Nobel) containing L. rhamnosus, Lacticaseibacillus casei, Lactiplantibacillus plantarum, Bifidobacterium animalis subsp. lactis, fructo-oligosaccharides, galacto-oligosaccharides, colostrum, and lactoferrin was found to be a significant risk factor for vancomycin-resistant Enterococcus colonization in premature infants. Although there was no direct link to determine causation, it was hypothesized that the probiotic mixture helped to mediate the acquisition and transfer of antibiotic resistance genes.
- Saxelin M, Chuang NH, Chassy B, et al. Lactobacilli and bacteremia in southern Finland 1989-1992. Clin Infect Dis 1996;22:564-6.
- Klein G, Zill E, Schindler R, et al. Peritonitis associated with vancomycin-resistant Lactobacillus rhamnosus in a continuous ambulatory peritoneal dialysis patient; organism identification, antibiotic therapy, and case report. J Clin Microbiol 1998;36:
- Kalima P, Masterton RG, Roddie PH, et al. Lactobacillus rhamnosus infection in a child following bone marrow transplant. J Infect 1996;32:165-7.
- Rautio M, Jousimies-Somer H, Kauma H, et al. Liver abscess due to Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis 1999;28:1159-60.
- MacGregor G, Smith AJ, Thakker B, Kinsella J. Yoghurt biotherapy: contraindicated in immunosuppressed patients? Postgrad Med J 2002;78:366-7.
- Land MH, Rouster-Stevens K, Woods CR, et al. Lactobacillus sepsis associated with probiotic therapy. Pediatrics 2005;115:178-81.
- De Groote MA, Frank DN, Dowell E, et al. Lactobacillus rhamnosus GG bacteremia associated with probiotic use in a child with short gut syndrome. Pediatr Infect Dis J 2005;24:278-80.
- Vahabnezhad E, Mochon AB, Wozniak LJ, Ziring DA. Lactobacillus bacteremia associated with probiotic use in a pediatric patient with ulcerative colitis. J Clin Gastroenterol. 2013;47(5):437-9.
- Sendil S, Shrimanker I, Mansoora Q, Goldman J, Nookala VK. Lactobacillus rhamnosus bacteremia in an immunocompromised renal transplant patient. Cureus. 2020;12(2):e6887.
- Albarillo FS, Shah U, Joyce C, Slade D. Lactobacillus rhamnosus Infection: A single-center 4-year descriptive analysis. J Glob Infect Dis. 2020;12(3):119-123.
- Pasala S, Singer L, Arshad T, Roach K. Lactobacillus endocarditis in a healthy patient with probiotic use. IDCases. 2020;22:e00915.
- Antoun M, Hattab Y, Akhrass FA, Hamilton LD. Uncommon pathogen, Lactobacillus, causing infective endocarditis: Case report and review. Case Rep Infect Dis. 2020;2020:8833948.
- Rossi F, Amadoro C, Gasperi M, Colavita G. Lactobacilli infection case reports in the last three years and safety implications. Nutrients. 2022;14(6):1178.
- Dani C, Coviello C C, Corsini I I, Arena F, Antonelli A, Rossolini GM. Lactobacillus Sepsis and Probiotic Therapy in Newborns: Two New Cases and Literature Review. AJP Rep. 2016;6(1):e25-9.
- Rubin IMC, Stevnsborg L, Mollerup S, Petersen AM, Pinholt M. Bacteraemia caused by Lactobacillus rhamnosus given as a probiotic in a patient with a central venous catheter: a WGS case report. Infect Prev Pract 2022;4(1):100200.
- Karime C, Barrios MS, Wiest NE, Stancampiano F. Lactobacillus rhamnosus sepsis, endocarditis and septic emboli in a patient with ulcerative colitis taking probiotics. BMJ Case Rep 2022;15(6):e249020.
- Sadowska-Krawczenko I, Paprzycka M, Korbal P, et al. Lactobacillus rhamnosus GG suspected infection in a newborn with intrauterine growth restriction. Benef Microbes. 2014;5(4):397-402.
- Kunz AN, Noel JM, Fairchok MP. Two cases of Lactobacillus bacteremia during probiotic treatment of short gut syndrome. J Pediatr Gastroenterol Nutr. 2004;38(4):457-8.
- Topcuoglu S, Gursoy T, Ovali F, Serce O, Karatekin G. A new risk factor for neonatal vancomycin-resistant Enterococcus colonisation: bacterial probiotics. J Matern Fetal Neonatal Med. 2015;28(12):1491-4.
Adverse-effects data: Natural Medicines, Therapeutic Research Center
Dosing
There is no single official dose for L. rhamnosus. Probiotic doses are usually measured in colony-forming units (CFU), and the amount used in studies varies widely by product and condition.
The best approach is to follow the directions on the product label and choose a reputable brand. Because effects can depend on the specific strain, it helps to pick a product that lists the exact strain. If you are unsure how much to take or whether it is right for you, ask your pharmacist or doctor.
Lacticaseibacillus Rhamnosus & Pregnancy
Lacticaseibacillus Rhamnosus & Breastfeeding
© 2026 Therapeutic Research Center
Pregnancy & lactation ratings: Natural Medicines, Therapeutic Research Center
References & further reading
The 34 references that drive our Lacticaseibacillus Rhamnosus monograph and interaction data, from the evidence-graded Natural Medicines (TRC Healthcare) database. Citations with a link open the study on PubMed or the publisher’s site.
- Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19.
- Saxelin M, Chuang NH, Chassy B, et al. Lactobacilli and bacteremia in southern Finland 1989-1992. Clin Infect Dis 1996;22:564-6. PubMed
- Klein G, Zill E, Schindler R, et al. Peritonitis associated with vancomycin-resistant Lactobacillus rhamnosus in a continuous ambulatory peritoneal dialysis patient; organism identification, antibiotic therapy, and case report. J Clin Microbiol 1998;36:
- Kalima P, Masterton RG, Roddie PH, et al. Lactobacillus rhamnosus infection in a child following bone marrow transplant. J Infect 1996;32:165-7. PubMed
- Rautio M, Jousimies-Somer H, Kauma H, et al. Liver abscess due to Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis 1999;28:1159-60.
- Rautava S, Kalliomaki M, Isolauri E. Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection against atopic disease in the infant. J Allergy Clin Immunol 2002;109:119-21. PubMed
- Kalliomaki M, Salminen S, Arvilommi H et al. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001;357:1076-1079. PubMed
- MacGregor G, Smith AJ, Thakker B, Kinsella J. Yoghurt biotherapy: contraindicated in immunosuppressed patients? Postgrad Med J 2002;78:366-7. PubMed
- Land MH, Rouster-Stevens K, Woods CR, et al. Lactobacillus sepsis associated with probiotic therapy. Pediatrics 2005;115:178-81.
- De Groote MA, Frank DN, Dowell E, et al. Lactobacillus rhamnosus GG bacteremia associated with probiotic use in a child with short gut syndrome. Pediatr Infect Dis J 2005;24:278-80. PubMed
- Beerepoot MA, ter Riet G, Nys S, van der Wal WM, de Borgie CA, de Reijke TM,Prins JM, Koeijers J, Verbon A, Stobberingh E, Geerlings SE. Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in p DOI
- Rautava S, Kainonen E, Salminen S, Isolauri E. Maternal probiotic supplementation during pregnancy and breast-feeding reduces the risk of eczema in the infant. J Allergy Clin Immunol. 2012;130(6):1355-60. PubMed
- Vahabnezhad E, Mochon AB, Wozniak LJ, Ziring DA. Lactobacillus bacteremia associated with probiotic use in a pediatric patient with ulcerative colitis. J Clin Gastroenterol. 2013;47(5):437-9. PubMed
- Wickens KL, Barthow CA, Murphy R, et al. Early pregnancy probiotic supplementation with Lactobacillus rhamnosus HN001 may reduce the prevalence of gestational diabetes mellitus: a randomised controlled trial. Br J Nutr. 2017;117(6):804-813.
- Topcuoglu S, Gursoy T, Ovali F, Serce O, Karatekin G. A new risk factor for neonatal vancomycin-resistant Enterococcus colonisation: bacterial probiotics. J Matern Fetal Neonatal Med. 2015;28(12):1491-4. PubMed
- Wickens K, Barthow C, Mitchell EA, et al. Maternal supplementation alone with Lactobacillus rhamnosus HN001 during pregnancy and breastfeeding does not reduce infant eczema. Pediatr Allergy Immunol. 2018 May;29(3):296-302.
- Husain S, Allotey J, Drymoussi Z, et al. Effects of oral probiotic supplements on vaginal microbiota during pregnancy: a randomised, double-blind, placebo-controlled trial with microbiome analysis. BJOG. 2020;127(2):275-284. PubMed
- Sendil S, Shrimanker I, Mansoora Q, Goldman J, Nookala VK. Lactobacillus rhamnosus bacteremia in an immunocompromised renal transplant patient. Cureus. 2020;12(2):e6887. PubMed
- Pellonperä O, Vahlberg T, Mokkala K, et al. Weight gain and body composition during pregnancy: a randomised pilot trial with probiotics and/or fish oil. Br J Nutr. 2020 Nov 4:1-11. PubMed
- Farr A, Sustr V, Kiss H, et al. Oral probiotics to reduce vaginal group B streptococcal colonization in late pregnancy. Sci Rep. 2020;10(1):19745. PubMed
- Albarillo FS, Shah U, Joyce C, Slade D. Lactobacillus rhamnosus Infection: A single-center 4-year descriptive analysis. J Glob Infect Dis. 2020;12(3):119-123. PubMed
- Pasala S, Singer L, Arshad T, Roach K. Lactobacillus endocarditis in a healthy patient with probiotic use. IDCases. 2020;22:e00915. PubMed
- Antoun M, Hattab Y, Akhrass FA, Hamilton LD. Uncommon pathogen, Lactobacillus, causing infective endocarditis: Case report and review. Case Rep Infect Dis. 2020;2020:8833948. PubMed
- Pellonperä O, Mokkala K, Houttu N, et al. Efficacy of fish oil and/or probiotic intervention on the incidence of gestational diabetes mellitus in an at-risk group of overweight and obese women: A randomized, placebo-controlled, double-blind clinical trial PubMed
- Davidson SJ, Barrett HL, Price SA, Callaway LK, Dekker Nitert M. Probiotics for preventing gestational diabetes. Cochrane Database Syst Rev. 2021;4(4):CD009951. PubMed
- Kirjavainen PV, Salminen SJ, Isolauri E. Probiotic bacteria in the management of atopic disease: underscoring the importance of viability. J Pediatr Gastroenterol Nutr. 2003;36(2):223-7. DOI
- Rossi F, Amadoro C, Gasperi M, Colavita G. Lactobacilli infection case reports in the last three years and safety implications. Nutrients. 2022;14(6):1178. PubMed
- Yefet E, Colodner R, Strauss M, Gam Ze Letova Y, Nachum Z. A randomized controlled open label crossover trial to study vaginal colonization of orally administered Lactobacillus reuteri RC-14 and rhamnosus GR-1 in pregnant women at high risk for preterm la
- Dani C, Coviello C C, Corsini I I, Arena F, Antonelli A, Rossolini GM. Lactobacillus Sepsis and Probiotic Therapy in Newborns: Two New Cases and Literature Review. AJP Rep. 2016;6(1):e25-9. PubMed
- Rubin IMC, Stevnsborg L, Mollerup S, Petersen AM, Pinholt M. Bacteraemia caused by Lactobacillus rhamnosus given as a probiotic in a patient with a central venous catheter: a WGS case report. Infect Prev Pract 2022;4(1):100200. PubMed
- Karime C, Barrios MS, Wiest NE, Stancampiano F. Lactobacillus rhamnosus sepsis, endocarditis and septic emboli in a patient with ulcerative colitis taking probiotics. BMJ Case Rep 2022;15(6):e249020.
- Ishihara Y, Kanda J, Tanaka K, et al. Severe oral infection due to Lactobacillus rhamnosus during induction chemotherapy for acute myeloid leukemia. Int J Hematol 2014;100(6):607-10. PubMed
- Sadowska-Krawczenko I, Paprzycka M, Korbal P, et al. Lactobacillus rhamnosus GG suspected infection in a newborn with intrauterine growth restriction. Benef Microbes. 2014;5(4):397-402. PubMed
- Kunz AN, Noel JM, Fairchok MP. Two cases of Lactobacillus bacteremia during probiotic treatment of short gut syndrome. J Pediatr Gastroenterol Nutr. 2004;38(4):457-8.
This information is for education only and is not a substitute for professional medical advice. Always check with your pharmacist or doctor before starting, stopping, or combining supplements and medications.
Parts of this content are provided by the Therapeutic Research Center, LLC.
DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.
© 2021 Therapeutic Research Center, LLC
Lacticaseibacillus Rhamnosus: Common Questions
What is Lacticaseibacillus Rhamnosus used for, and does it work?
Does Lacticaseibacillus Rhamnosus interact with prescription medications?
How are Lacticaseibacillus Rhamnosus interactions rated?
Is it safe to take Lacticaseibacillus Rhamnosus with my medications?
Where does this Lacticaseibacillus Rhamnosus interaction information come from?
What is Lacticaseibacillus Rhamnosus used for?
Is it the same as Lactobacillus rhamnosus?
Is it safe to take every day?
Can children take it?
Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy
Have a question about Lacticaseibacillus Rhamnosus?
Our pharmacists answer your medication & supplement questions — free.